Vyne Therapeutics Inc.

13F holders, Q3 2024 (September 30)
1holders −1
0new positions
1sold out
$1.88avg. 13F price*

At the end of Q3 2024, 1 institutions reported holding Vyne Therapeutics Inc. in their 13F filings, down 1 from Q2 2024. 0 opened new positions and 1 sold out. The largest holder was Staley Capital Advisers Inc. ($69K).

Company
Vyne Therapeutics Inc.
CUSIP
92941V209
Latest filing quarter
Q2 2026

History

Number of 13F holders

0123 Q1 2024: 2Q1 2024Q2 2024: 2Q2 2024Q3 2024: 1Q3 2024Q4 2024: 1Q4 2024Q1 2025: 1Q1 2025Q2 2025: 2Q2 2025Q3 2025: 3Q3 2025Q4 2025: 2Q4 2025Q1 2026: 1Q1 2026Q2 2026: 1Q2 2026

Total Exit/New Position Q2 2024 → Q3 2024

InstitutionsTotal Value
New Positions0$0
Exits1$37

All 13F filers, Q2 2024 → Q3 2024: 19 shares sold, net −19 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 1 holders

Staley Capital Advisers Inc. 0.00% No change 36,472 $69K

"% of holder's portfolio" is VYNE THERAPEUTICS INC's weight in each manager's 13F, not the share of Vyne Therapeutics Inc. the manager owns.